These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 21684478)

  • 1. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Samy W; Hassanian MA
    Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new marker for lipid peroxidation: serum paraoxonase activity in non-alcoholic steatohepatitis.
    Başkol M; Başkol G; Deniz K; Ozbakir O; Yücesoy M
    Turk J Gastroenterol; 2005 Sep; 16(3):119-23. PubMed ID: 16245219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
    Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
    Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Investigation of oxidative stress and antioxidant defense in patients with hepatitis B virus infection and the effect of interferon-alpha plus lamivudine combination therapy on oxidative stress].
    Acar A; Görenek L; Aydin A; Eyigün CP; Eken A; Sayal A; Pahsa A
    Mikrobiyol Bul; 2009 Jul; 43(3):411-23. PubMed ID: 19795616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease.
    Das KS; Balakrishnan V; Mukherjee S; Vasudevan DM
    Scand J Clin Lab Invest; 2008; 68(4):323-34. PubMed ID: 18609067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.
    Martín-Castillo A; Castells MT; Adánez G; Polo MT; Pérez BG; Ayala I
    Biomed Pharmacother; 2010 Apr; 64(4):275-81. PubMed ID: 19932590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase.
    Kassai A; Illyés L; Mirdamadi HZ; Seres I; Kalmár T; Audikovszky M; Paragh G
    Clin Biochem; 2007 Jan; 40(1-2):1-5. PubMed ID: 16999950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
    Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
    Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
    Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.
    Yalniz M; Bahcecioglu IH; Kuzu N; Poyrazoglu OK; Bulmus O; Celebi S; Ustundag B; Ozercan IH; Sahin K
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2009-14. PubMed ID: 17914984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
    Nordøy A; Hansen JB; Brox J; Svensson B
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):7-16. PubMed ID: 11383326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status.
    Nagila A; Permpongpaiboon T; Tantrarongroj S; Porapakkham P; Chinwattana K; Deakin S; Porntadavity S
    Pharmacol Rep; 2009; 61(5):892-8. PubMed ID: 19904013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orlistat increases serum paraoxonase activity in obese patients.
    Audikovszky M; Pados G; Seres I; Harangi M; Fülöp P; Katona E; Illyés L; Winkler G; Katona EM; Paragh G
    Nutr Metab Cardiovasc Dis; 2007 May; 17(4):268-73. PubMed ID: 17134960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract.
    Hashim Z; Zarina S
    Clin Biochem; 2007 Jun; 40(9-10):705-9. PubMed ID: 17466963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
    Harangi M; Mirdamadi HZ; Seres I; Sztanek F; Molnár M; Kassai A; Derdák Z; Illyés L; Paragh G
    Transl Res; 2009 Apr; 153(4):190-8. PubMed ID: 19304278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.